Company Overview and News
BEIJING (Oct 16): Beijing is keen to show results after four rounds of policy easing, so China’s big banks are playing along, highlighting their efforts to boost lending to cash-starved small firms, offering collateral waivers and setting loan targets.
CICHY 55BC CBQS CICHF CCB 0939
Beijing is keen to show results after four rounds of policy easing, so China's big banks are playing along, highlighting their efforts to boost lending to cash-starved small firms, offering collateral waivers and setting loan targets.
CICHY 55BC CBQS CICHF CCB 0939
BEIJING (Reuters) - Beijing is keen to show results after four rounds of policy easing, so China’s big banks are playing along, highlighting their efforts to boost lending to cash-starved small firms, offering collateral waivers and setting loan targets.
CICHY 55BC CBQS CICHF CCB 0939
BEIJING: Singapore’s state investment firm, Temasek Holdings Pte, has held talks with Chinese authorities about acquiring a stake in Anbang Insurance Group Co. as well as some of its assets, according to people with knowledge of the matter. Temasek has been examining a potential deal for several months, the people said, asking not to be identified because the discussions are private. The S$308 billion ($224 billion) investment firm isn’t currently in any active negotiations about an Anbang transaction, according to two people with knowledge of its deliberations.
CICHY CHIB 55BC CBQS CICHF CCB CKGOY 0939
Oct 11, 2018 (LBO) – A large gathering of Institutional Investors based in London showed a keen interest in investing in Sri Lankan equities while attending an Invest Sri Lanka Forum held at the London Stock Exchange recently.
DIAL UBNC JKELF 55BC CBQS NTB HNB SAMP HPWR SPEN JKH LSE LNSTY SUN JKEHY
Sources say Chinese regulators led by the country’s central bank are set to initially shortlist at least 50 of the country’s largest lenders, insurers and brokerages as possible ‘systemically important financial institutions’
STAN 55BC CBQS CICHY 580001 STAB STAN STAC 2888 SCBFF CICHF CCB 0939
China accounts for about 37 per cent of assets under management in the industry today and is expected to grow at a pace of more than 17 per cent annually for the next five years, according to consulting firm
Hong Kong stocks declined across the board on Thursday because a rally in the US dollar overnight caused the city’s currency as well as offshore yuan to weaken, triggering pessimism over the economic outlook.
CICHY 55BC 0700 SOTGY CBQS 2382 CICHF SNPTF CCB 0939
The world remains vulnerable to another financial meltdown as a result of "side effects" from extraordinary measures to prevent a repeat of the Great Depression, the International Monetary Fund has warned.
Hong Kong stocks extended losses on Wednesday to close at their lowest in two weeks, tracking declines in the US and as investors remained cautious in the wake of China’s slowing economy that could be squeezed further in the prolonged trade war with the US.
STAN 55BC SCHYF WYNMF GXYEF CBQS GXYYY AAIGF 1128 0027 580001 STAB STAN STAC 2888 SCBFF 1928 AAGIY SCHYY WYNMY
Oct 1 (Reuters) - Egypt’s stock index fell 1.2 percent on Monday because of concerns that its currency could be vulnerable, while Saudi Arabia and United Arab Emirates markets rose, buoyed in part by high oil prices.
Oct 01, 2018 (LBO) – Fitch Ratings has affirmed the Long-Term Issuer Default Ratings (IDRs) of nine Sri Lanka-based banks and has assigned a stable outlook for these banks.
DFCC SEYB 55BC CBQS NTB NDB HNB SAMP
Hong Kong’s de facto central bank lifts its base lending rate by 25 basis points to 2.5 per cent, bringing the tipping point closer to when the city’s commercial banks will raise their prime rate. That would translate into higher mortgage payments.
CGASY 55BC CBQS
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...